Mallinckrodt and Sucampo Pharmaceuticals announced an agreement in which Mallinckrodt will acquire Sucampo for approximately $1.2 billion.
The transaction was approved by the boards of directors of both companies, according to a joint press release.
The deal comprises all commercial and development assets of Sucampo, including Rescula (unoprostone isopropyl ophthalmic solution 0.15%), which is indicated for ocular hypertension and open-angle glaucoma. Rescula is marketed in Japan and has annual net sales of approximately $9 million.
Sun Acquisition Co., a subsidiary of Mallinckrodt, will
Uncategorized